Omburtamab I-131

N/A

Report date: 2025/09/08 14:40:40

Base Information

Drug NameOmburtamab I-131
Drug Alias Name131I-omburtamab碘[131I]-OmburtamabOmblastys131I-8H9-(B7-H3)131-I-8H9 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive therapeutic agent +[5] 
Mechanisms of ActionIonising radiation emittersCD276 antigen inhibitors
TargetsCD276 antigen
Therapy Area/IndicationsCNS Embryonal TumorCentral Nervous System DiseasesNeoplasm Metastasis +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesDenmarkSpain +[5] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesY-Mabs Therapeutics IncAdium Pharma SATakeda Pharmaceutical Co Ltd +[5] 
Inactive CompaniesY-Mabs Therapeutics AsMemorial Sloan Kettering Cancer Center
Active IndicationsNeuroblastoma
Inactive IndicationsCNS Embryonal TumorCentral Nervous System DiseasesNeoplasm Metastasis +[6] 

Other Information

ATC CodeN/A
Related LinksN/A